• 1
    Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 2003; 61: 12336.
  • 2
    Subramaniam M, Ng C, Chong SA et al. Metabolic differences between Asian and Caucasian patients on clozapine treatment. Hum. psychopharmacol. 2007; 22: 21722.
  • 3
    Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H. Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: A 1-year naturalistic follow-up study. J. Clin. Psychopharmacol. 2009; 29: 3945.
  • 4
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC, 1994.
  • 5
    Takeuchi H, Suzuki T, Uchida H et al. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: Add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. J. Clin. Psychopharmacol. 2008; 28: 5403.
  • 6
    Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: A retrospective chart review. J. Clin. Psychiatry 2007; 68: 4069.
  • 7
    Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008; 33: 98594.